Occasional reviews

Interactions between corticosteroids and β agonists

Department of
Medicine, Dunedin
School of Medicine,
P O Box 913, Dunedin,
New Zealand
D R Taylor
R J Hancox

Correspondence to:
Dr D R Taylor
e-mail: robin.taylor@
stonebow.otago.ac.nz

Received 5 January 2000
Accepted for publication
20 January 2000

D R Taylor, R J Hancox

Inhaled corticosteroids and β agonists are the most frequently prescribed drugs in the management of chronic asthma. Current guidelines emphasise their complementary role. Inhaled corticosteroids are the treatment of choice for all but the mildest of disease. Short acting β agonists are recommended for "as required" relief of asthma symptoms,

whereas long acting agents are indicated as a supplement to anti-inflammatory therapy if breakthrough symptoms persist.¹ Thus, co-prescribing is commonplace. However, despite dynamic interactions between endogenous glucocorticoids and catecholamines in vivo, it is only recently that interest in the possibility of drug interactions has developed. Two topical and clinically relevant questions arise. Firstly, do positive interactions occur, thus providing theoretical justification for current trends to use combination products incorporating a long acting β agonist and a corticosteroid? Secondly, do negative interactions occur which might explain the apparent paradox that, despite increasing use of the two therapies over the last 30 years, the overall burden of asthma morbidity in most western countries has continued to increase?²

Effects of glucocorticoids on β receptor function

Endogenous adrenal glucocorticoids have an important facilitatory effect on β receptor function in vivo. In animals adrenalectomy results in a generalised loss of responsiveness to catecholamines.^{3,4} Conversely, the presence of glucocorticoids enhances β receptor mediated responses: myocardial contractility, hepatic and voluntary muscle glucose metabolism, and bronchial smooth muscle relaxation have been shown to increase.⁴ These actions occur at physiological concentrations of glucocorticoid.

At least two mechanisms are proposed whereby glucocorticoids modify β receptor function. The first is by regulating the coupling of β receptors to G proteins and hence adenyl cyclase activation (fig 1). The degree of coupling determines cell responsiveness to β receptor stimulation.⁵ Following exposure to exogenous β agonist, uncoupling occurs rapidly by phosphorylation of the receptor (desensitisation). There are a number of phosphorylation pathways, including β adrenoceptor kinase (β -ARK),^{6,7} and these constitute the first step towards the development of drug tolerance. Exposure to corticosteroids restores receptors to their previously sensitised state.⁸

The second is that glucocorticoids can upregulate previously downregulated β receptor function after chronic β agonist exposure. Downregulation is characterised by receptor internalisation and degradation,⁹ reversal of which requires new receptor synthesis. Activa-

Figure 1 Putative intracellular mechanisms for interaction between β agonists and corticosteroids. (1) The steroid-glucocorticoid receptor complex upregulates β receptors by enhancing β receptor coupling with G protein and/or preventing downregulation following β receptor activation. (2) Binding between the activated glucocorticoid receptor and CREB in the cytoplasm may inhibit translocation to the nucleus. (3) "Cross talk" between the glucocorticoid receptor, CREB, and other nuclear transcription factors. (4) "Cross talk" between the glucocorticoid receptor and CREB in the nucleus. (5) The glucocorticoid receptor and CREB may compete for or synergistically bind protein co-factors such as CBP which are required for coupling with RNA polymerase and activation of response elements in the promoter regions of target genes. (6) Direct phosphorylation of protein co-factors such as CBP may alter their activity. (7) The presence of both GREs and CREs in the promoter regions of target genes may mutually enhance or inhibit their effects on gene transcription. (8) The promoter region of the β receptor gene contains GREs which may enhance or suppress synthesis of the β receptor protein. (9) The promoter region of the glucocorticoid receptor gene contains CREs which may enhance or suppress synthesis of the glucocorticoid receptor protein. (10) A cAMP-dependent mechanism enhances the stability of messenger RNA for the glucocorticoid receptor increasing receptor levels.¹⁷ AC = adenylate cyclase; ATP = adenosine triphosphate; BA = β agonist; BR = β adrenoceptor; CBP = CREB binding protein; CRE = cAMP response element; CREB = cAMP response element binding protein; cAMP = cyclic adenosine monophosphate; GR = glucocorticoid receptor; GRE = glucocorticoid response element; Gs = stimulatory G protein; HSP = heat shock protein 90; mRNA = messenger RNA; PKA = protein kinase A; RP = RNA polymerase; S = steroid drug molecule; TF = transcription factor.

tion of glucocorticoid response elements (GREs) in the promoter region of the β receptor gene causes an increase in the rate of gene transcription and hence of receptor numbers.^{10–15}

Effects of β agonists on glucocorticoid receptor function

Inactive glucocorticoid receptors (GRs) are bound to protein complexes (including heat shock protein, HSP-90) in the cytosol. After ligand binding, activated GRs dissociate and translocate to the nucleus where they bind to glucocorticoid response elements (GREs) in the promoter region of target genes. The effect of catecholamines on the normal function of GRs and GREs has not been studied in detail. Forskolin, which increases intracellular cyclic AMP levels (thereby mimicking β_2 receptor activation), has been shown to increase rat hepatoma cell GR numbers and potentiate the production of dexamethasone induced neurotensin from the rat hypothalamic cells.¹⁶ Forskolin may also antagonise the downregulation of GRs induced by dexamethasone.¹⁷ These actions provide indirect evidence that β agonists, which also enhance intracellular cAMP levels, might enhance GR function.

Glucocorticoids mediate many of their anti-inflammatory effects by either activating or repressing gene transcription of cytokines. In addition to the binding of activated GRs to GREs in the nucleus, this may also occur indirectly when activated GRs interact with pro-inflammatory nuclear transcription factors—for example, AP-1 or NF-kappa B (NF- κ B)—to suppress their effects on the upregulation of pro-inflammatory cytokine production (fig 1).^{18, 19} Beta agonists modify gene transcription by increasing intracellular levels of cAMP and activating the nuclear transcription factor cAMP response element binding protein (CREB). In turn this binds to cAMP response elements (CREs) on target genes. So-called “cross talk” between these transcription factors has been postulated as a mechanism for interactions between β agonist and corticosteroid drugs. It is likely that “cross talk” includes competitive binding of protein co-factors such as CREB binding protein (CBP) or the related P300 which are necessary for the activation of transcription factor response elements to GRs.²⁰ Interactions between GREs and closely related CREs in the promoter region of genes may also be important.

There is evidence that the effects of β agonists and glucocorticoids on nuclear transcription factors are mutually inhibitory. Incubation of rat lung with salbutamol and fenoterol inhibits GR binding to GREs, while incubation with dexamethasone inhibits the binding of CREB to CREs.²¹ The extent of mutual inhibition is of the order of 40–50%. Similar effects have been described in the human lung.^{22, 23} Despite this, in a clinical study designed to examine transcription factor changes in bronchial mucosa during treatment of mild asthma with terbutaline and budesonide singly and in combination, Hancox *et al* found no evidence of a negative interaction.²⁴ Although DNA binding of the transcription

factor NF- κ B was reduced in bronchial mucosa and GR binding increased with regular inhaled budesonide, the simultaneous administration of regular terbutaline did not alter the binding activity of either.²⁴

In other studies in human bronchial epithelial cells an inhibitory effect of terbutaline on GR binding responses to budesonide has been shown, but occurred only when the β agonist was administered simultaneously; the effects of prior exposure to corticosteroid were unaffected by the subsequent addition of terbutaline.²⁵ Thus, the timing of exposure to the two agents may be of relevance in determining possible interactions. In contrast, in another study both salbutamol and salmeterol have been shown to enhance the activation of GC receptors and their binding to nuclear GREs.²⁶

The results of other laboratory studies designed to evaluate possible interactions between β agonists and glucocorticoids on inflammatory cells and their cytokines have also been inconsistent. Salmeterol has been shown to enhance the steroid induced inhibition of allergen activated monocytes²⁷ and also appears to potentiate fluticasone induced apoptosis in activated human eosinophils (by a factor of 2–3).²⁸ Similarly, in airway smooth muscle cells the inhibitory effect of dexamethasone on tumour necrosis factor (TNF)- α mediated interleukin-8 production was potentiated by simultaneous incubation with both salbutamol and salmeterol.²⁹ In contrast, Seldon *et al* have studied the effect of salbutamol on dexamethasone induced inhibition of TNF- α and GM-CSF production from stimulated monocytes but, even at high concentrations of salbutamol, no important interaction was observed.³⁰ Other in vitro data suggest that, at pharmacological concentrations, the presence of either isoprenaline or salbutamol may actually impair the beneficial actions of steroid. Nielson *et al*³¹ have shown that the effects of dexamethasone on eosinophil superoxide production and apoptosis are reduced in a dose dependent manner by both of these short acting β agonists.

A number of biological and pharmacological factors might account for the apparently conflicting outcomes from these studies. They include tissue dependent differences in receptor function, variations in the in vitro drug concentrations used and the duration of exposure, and differing pharmacological properties of the drugs used—for example, partial versus full agonist or short acting versus long acting. Nevertheless, they provide some of the background against which potential interactions between β agonists and inhaled corticosteroids in patients requiring chronic treatment have been investigated.

Clinical interactions: acute severe asthma REVERSING DESENSITISATION AND DOWNREGULATION

Although the principal mode of action of corticosteroids in acute asthma is to control airway inflammation, several studies indicate that reversing β receptor desensitisation and

downregulation caused by prior β agonist treatment may be important. In animal studies a bolus of corticosteroid reverses tolerance to the protective effects of isoprenaline against non-specific airway responsiveness.³² However, at least in vitro, the magnitude of this effect appears to differ depending on which drugs are used.³³ In humans, single doses of either intravenous prednisolone³⁴ or even inhaled beclomethasone³⁵ have been shown to restore the bronchodilator response to isoprenaline and fenoterol, respectively. Similarly, Tan *et al*³⁶ have shown that tolerance to the bronchodilator effects of inhaled formoterol may be rapidly reversed by a single dose of intravenous corticosteroid. The apparently short time frame for this change contrasts with that for the formation of cytokines and inflammatory cell infiltration in the late asthmatic response, suggesting that the initial benefits of steroid therapy in acute asthma are due to their permissive effect on β receptor function rather than suppression of pro-inflammatory pathways. This might also explain the clinical observation that, in acute severe asthma, the co-administration of corticosteroid either systemically or by the inhaled route results in an enhanced rate of recovery of lung function compared with β agonist or corticosteroid alone.³⁷⁻³⁸

Although interactions between β agonists and corticosteroids in acute asthma are likely to be beneficial, there are theoretical reasons why this might not always be the case. A number of hypotheses have been advanced to explain the relationship between the use of inhaled β agonists and the two recent "epidemics" of asthma mortality.³⁹ Among them is the possibility that, in association with the hypoxia of acute severe asthma, overuse of β agonists might precipitate death by cardiac arrhythmia.⁴⁰ In patients who have been taking β agonists frequently or regularly, administering systemic corticosteroids might re-sensitise myocardial as well as bronchial smooth muscle β receptors, thus theoretically increasing the possibility of arrhythmias. In laboratory animals corticosteroid administration has been shown to increase the cardiac toxicity of catecholamines.⁴¹ Recently, Aziz *et al* have shown that downregulation of human heart rate responses to salbutamol during treatment with the long acting β agonist formoterol was modified by concomitant use of inhaled steroid.⁴² Likewise, cardiovascular responses to emergency β agonist drugs may be increased in patients who have previously received treatment with inhaled corticosteroids.⁴³ In contrast, in healthy volunteers the use of oral prednisone failed to potentiate the effects of β agonist on heart rate or QTc interval.⁴⁴ Given that death from acute severe asthma is more likely to be the result of respiratory failure than cardiac causes,⁴⁵ it seems unlikely that recovery or even enhancement of the downregulated cardiovascular effects of β agonist by corticosteroid during acute severe asthma is clinically important.

Clinical interactions: chronic asthma

PROTECTION AGAINST THE DEVELOPMENT OF TOLERANCE

If corticosteroids are of benefit in restoring β receptor numbers and function in acute asthma, the question arises: do they offer protection against the development of tolerance when administered as chronic therapy? Unfortunately, since no firm relationship has been established between β agonist tolerance during long term use of either short or long acting agents and asthma control, the clinical relevance of this question is speculative. Nevertheless, a number of studies have been carried out to establish whether inhaled corticosteroids may have a prophylactic role in preventing β agonist tolerance.

The results of most studies indicate that inhaled corticosteroids do not modify the development of tolerance during treatment with short acting agents.⁴⁶⁻⁴⁹ In a recent study by Hancox *et al*⁵⁰ clear evidence of tolerance to the bronchodilator action of inhaled β agonist was seen in 34 asthmatic patients following six weeks treatment with regular inhaled terbutaline in a dose of 1 mg four times daily. After inducing bronchoconstriction with methacholine, the acute response to sequential doses of inhaled salbutamol was significantly reduced compared with placebo but the addition of regular budesonide to terbutaline in a dose of 400 μ g twice daily did not prevent this effect. In one in vitro study some protection against the development of tolerance was achieved with the administration of dexamethasone,¹⁵ which is arguably a more potent corticosteroid. However, in a clinical study by Molema *et al* in which a range of doses of inhaled beclomethasone was given, tolerance to the acute effects of inhaled salbutamol remained unchanged.⁴⁷ It therefore seems unlikely that the use of even high doses of inhaled corticosteroids will confer protection, even if avoiding tolerance were deemed to be clinically desirable.

A similar picture has emerged for the long acting β agonists, particularly with regard to the loss of protective effect against bronchoconstrictor stimuli afforded by single doses of a short acting drug during long term treatment with a long acting agent.⁵¹⁻⁵⁶ In general, inhaled corticosteroids do not prevent the advent of tolerance, although here the evidence is perhaps less clear. Recently, Giannini *et al* have reported that inhaled beclomethasone partially reverses the loss of protective effect of salmeterol against allergen challenge.⁵⁷ In another study with healthy volunteers Tan *et al* found that oral steroid prevented downregulation of systemic responses to salbutamol during long term treatment with formoterol.⁵⁸

CLINICAL INTERACTIONS: SHORT ACTING β AGONISTS

In the late 1980s case control studies carried out in New Zealand identified an association between asthma mortality and the prescription of the β agonist fenoterol. The risk of death was greatest among those requiring continuous treatment with oral prednisone.⁵⁹⁻⁶¹ This may not be surprising since these patients had more

Figure 2 Changes in PC₂₀ allergen (doubling doses) 33 hours after cessation of treatment with placebo, terbutaline, budesonide, and their combination. The increase in PC₂₀ which occurred with budesonide was significantly greater than for the combination of terbutaline and budesonide. Shaded areas = interquartile ranges. Reproduced from Wong *et al*⁶⁸ with permission.

severe asthma, but it did raise the possibility of an adverse interaction. Further, the results of several investigations have found that airway inflammation may be increased during monotherapy with a short acting β agonist.⁶²⁻⁶⁴ Thus, individual case reports have suggested that reducing, or even withdrawing, short acting β agonist treatment may result in clinical improvement and a significant reduction in steroid requirements.⁶⁵⁻⁶⁷ These data have generated the hypothesis that the benefits of corticosteroid treatment may be compromised or, alternatively, that the need for anti-inflammatory therapy may be increased as a result of β agonist use and an adverse interaction between the two drugs.

Other clinical studies have offered support for this possibility. Wong *et al*⁶⁸ showed that the addition of regular terbutaline treatment resulted in significant impairment of the reduction in bronchial hyperresponsiveness to allergen resulting from inhaled budesonide (fig 2).

Similarly, in a controlled crossover study Cockcroft *et al*⁶⁹ showed that bronchial responsiveness to allergen was increased after treat-

ment with regular salbutamol, reduced after treatment with budesonide, and intermediate when both drugs were used in combination.

Given this background, there has been a need for appropriately designed studies to confirm whether these observations are relevant to asthma control during long term combined therapy with inhaled corticosteroids and β agonists. A number of investigations have compared the addition of inhaled corticosteroids to β agonist treatment alone.⁷⁰⁻⁷⁵ Their results have been consistent: symptoms, pulmonary function, bronchial hyperresponsiveness, and exacerbation rates are improved using combined therapy. However, comparisons between combined treatment and inhaled corticosteroids alone, which are much more relevant to answering the question of a possible adverse interaction between the two drugs, have been fewer. Their results are summarised in table 1.^{63 76-81}

We have recently reported the results of two placebo controlled, four way, crossover studies designed to evaluate interactions between β agonists and inhaled corticosteroids.^{63 81} Neither investigation provided evidence that short acting β agonists reduced the clinical benefits of inhaled corticosteroids. In the larger study comprising 61 patients with mild to moderate asthma⁸¹ combined treatment with inhaled terbutaline (1 mg four times daily) and inhaled budesonide (800 μ g daily) over six weeks was ranked best of the four treatments, and achieved significant improvements in asthma control compared with budesonide alone. A similar positive interaction was noted for morning peak flows which showed a greater increase during combined treatment (compared with placebo) than the sum of the increases for terbutaline or budesonide given alone (fig 3) although, interestingly, this pattern was not true for FEV₁. A simple explanation for these results is that terbutaline enhanced airway deposition of the budesonide and hence overall improvement. However, given the *in vitro* evidence already cited, a more complex interaction seems likely. The possibility that inhaled steroid may have offered

Table 1 Studies comparing short acting β agonists in combination with inhaled corticosteroids with inhaled corticosteroid alone

Reference	No. of patients	Study design	Results	Comments
Dahl <i>et al</i> ⁶⁶	37	DB, crossover, 3 weeks. Oral terbutaline/inhaled budesonide/both	Higher peak flows + fewer nocturnal awakenings with combination	Oral terbutaline used. Small differences between treatments
Bennati <i>et al</i> ⁷⁷	30	DB, parallel group, 1 month. Salbutamol/beclomethasone/both	PC ₂₀ (methacholine) higher after combination than beclomethasone alone (NS)	Salbutamol used prn in beclomethasone group. Small numbers of subjects
Selroos <i>et al</i> ⁷⁸	12	DB, crossover, 3 weeks. Terbutaline + budesonide/budesonide	FEV ₁ higher with combination. No difference in peak flow or PD ₂₀ (histamine)	Abstract report. Small numbers of subjects
Wilding <i>et al</i> ⁷⁹	16	DB, crossover, 2 weeks. Terbutaline + budesonide/budesonide	Evening peak flow higher with combination. Morning peak flow also higher (NS).	Small differences only. Small numbers of subjects
Barnes <i>et al</i> ⁸⁰	74	DB, crossover, 4 weeks. Terbutaline/budesonide/ both	Peak flow higher with combination. Fewer symptoms with combination	Very low dose terbutaline used. β agonist used prn throughout
Hancox <i>et al</i> ⁸¹	61	DB, placebo controlled, crossover, 6 weeks. With/without ipratropium used as supplement. Terbutaline/budesonide/ both/placebo	Combination treatment was highest ranked. Morning peak flows higher with combination than sum of increments with single treatments.	High doses of terbutaline used (4000 μ g/day) to maximise any possible adverse interaction.
Aldridge <i>et al</i> ⁸³	34	DB, placebo controlled, crossover, 6 weeks. Ipratropium used as supplement. Terbutaline/budesonide/ both/placebo	BHR to hypertonic saline and sputum eosinophils increased with terbutaline	Pro-inflammatory actions of terbutaline not modified by combination of budesonide with terbutaline

DB = double blind; NS = not statistically significant; BHR = bronchial hyperresponsiveness; FEV₁ = forced expiratory volume in one second; PD₂₀ = provocative dose causing fall in FEV₁ of 20% or more.

Figure 3 Mean morning and evening peak flow rates during six weeks treatment with regular inhaled terbutaline, budesonide, their combination, and placebo. Morning peak flows were higher when terbutaline was added to budesonide ($p < 0.002$) whereas, when compared with placebo, terbutaline alone conferred no significant improvement. Reproduced from Hancox *et al*⁶¹ with permission.

protection against the development of tolerance has been investigated and discounted.⁵⁰

Similar clinical outcomes were obtained in a second separate study comprising 34 patients.⁶³ However, in that investigation there was a significant reduction in PD_{15} for hypertonic saline and a significant increase in the percentage of eosinophils in induced sputum during treatment with terbutaline, indicating that monotherapy with the short acting β agonist had a permissive effect on airway inflammation (fig 4). This adverse outcome was not modified by the addition of budesonide. Indeed, the pattern of results for these end points was similar to that previously described by Wong *et al*⁶⁸ and Cockcroft *et al*⁶⁹—namely, there was some impairment of the benefits of treatment with inhaled corticosteroids when the β agonist was added without apparently affecting asthma control.

Taken together, the results of these recent studies suggest that, even though inhaled corticosteroids do not appear to prevent the pro-inflammatory effects of short acting β agonists, this is unlikely to be of clinical significance, at least in patients with mild or moderate asthma taking “normal” doses of either drug. In fact, a beneficial interaction appears to occur in most patients. The results suggest that a β agonist facilitates the actions of inhaled corticosteroids, perhaps simply by improving airway drug deposition or, alternatively, by enhancing the anti-inflammatory effects of inhaled corticosteroids at a subcellular level.^{26–28}

CLINICAL INTERACTIONS: LONG-ACTING β AGONISTS

Current guidelines for the management of chronic asthma support the addition of a long acting β agonist in patients whose asthma remains inadequately controlled with anti-inflammatory therapy and “as required” bronchodilator.¹ As monotherapy, inhaled corticosteroid achieves greater control of asthma than long acting β agonist alone.^{82–83} However, the addition of a long acting agent results in greater improvements in symptoms

and lung function than increasing the dose of inhaled corticosteroid.^{84–90}

Although in some studies these outcomes do not appear to translate into a reduction in asthma exacerbations,^{91–92} this is perhaps because these studies were not primarily designed to evaluate this clinical end point. In contrast, in the FACET study⁹³ the addition of regular formoterol in a dose of 12 μ g twice daily to either low dose (200 μ g/day) or high dose (800 μ g/day) budesonide reduced severe exacerbation rates by 26% in each instance. However, the reduction in severe asthma episodes for patients on low dose steroid was still best achieved by increasing the anti-inflammatory therapy (49%). Even in patients on maintenance treatment with inhaled corticosteroids and whose asthma is considered to be stable, further benefits may be achieved by adding a long acting β agonist. In the study by Taylor *et al* the use of salmeterol resulted in a 45% reduction in major exacerbations among patients with stable asthma, 92% of whom were already taking inhaled corticosteroids.⁹⁴ Leblanc *et al* have reported that the benefits of long acting β agonists are greater in patients already receiving inhaled corticosteroids than in those who are not already on anti-inflammatory therapy.⁹⁵ Salmeterol has also been shown to permit a

Figure 4 Changes in (A) bronchial hyperresponsiveness to hypertonic saline (PD_{15} saline) and (B) percentage of eosinophils in induced sputum at the end of six weeks treatment with inhaled terbutaline (1 mg four times daily), budesonide (400 μ g twice daily), combined treatment, and placebo given to 34 subjects in a randomised crossover sequence. Reproduced from Aldridge *et al*⁶³ with permission.

reduction in maintenance dosage of inhaled corticosteroid (median reduction of 400 µg beclomethasone per day compared with 0 µg per day during the placebo period) without any apparent increase in symptoms or adverse change in lung function although, again, exacerbation rates were not reported as a study end point.⁹⁶

Although the design of most of these studies may not permit final conclusions to be drawn, their results suggest that the benefits of long acting β agonists are likely to be greatest among patients already taking inhaled corticosteroids, thus raising the possibility that a positive interaction may be occurring. This seems more plausible than that long acting β agonists have intrinsic anti-inflammatory effects, clear evidence for which has not emerged. These data have formed the basis upon which the role of fixed dose combination products is now being investigated.

Conclusions

Both positive and negative interactions between corticosteroids and β agonists may occur; both have been demonstrated in vitro. On the one hand, β agonists may potentiate steroid induced repression of some cytokines while corticosteroids upregulate β receptor mRNA transcription, thus restoring β receptor function. On the other, mutual inhibition of the binding of nuclear transcription factors has been shown. These apparently divergent results may be the result of methodology; there have been important differences between tissue preparations, drug concentrations, and duration of drug exposure in the various studies. As yet we cannot conclude that these interactions—whether positive or negative—occur consistently or whether these in vitro data are relevant to the in vivo situation.

In clinical studies interactions between β agonists and corticosteroids appear to be predominantly positive. In acute severe asthma the interaction is beneficial: the administration of corticosteroid enhances the bronchodilator response to β agonist by reversing desensitisation and downregulation of β receptors. In chronic asthma there is little evidence that corticosteroid prevents β receptor downregulation. Despite this, combinations of the two drugs have been found to improve asthma control and reduce exacerbation rates. This is particularly true for long acting β agonists. The exact mechanism remains unclear. There is also the possibility that, because of a positive interaction, long acting β agonists may have “steroid enhancing” or “steroid sparing” effects. However, the use of these terms ought to be very cautiously applied: the minimum dose requirement for inhaled corticosteroids in combination therapy remains to be defined and, given that the use of long acting β agonists as monotherapy is less effective than inhaled corticosteroids alone, it is certainly not zero.

Current clinical data provide reassurance that in most patients the benefits of inhaled corticosteroids are not being compromised by β agonist use and, at least for long acting agents, are likely to be enhanced. Nevertheless,

studies designed specifically to evaluate airway inflammation and bronchial hyperresponsiveness indicate that short acting β agonists may have pro-inflammatory effects and that their magnitude is not modified by treatment with inhaled corticosteroids. It remains possible that, in patients with more severe asthma or those using higher doses of drug or for longer periods of time, the pro-inflammatory actions of short acting β agonists counterbalance the benefits of inhaled corticosteroids. There are sufficient in vitro data to support this possibility. This might explain the adverse effect of β agonists on asthma control that has been observed in some studies despite concomitant anti-inflammatory treatment when a potent agent at relatively high doses has been used.^{97 98}

- 1 British Thoracic Society. The British guidelines on asthma management: 1995 review and position statement. *Thorax* 1997;52(Suppl 1):S1–21.
- 2 Sears MR. Epidemiology of asthma. In: Barnes PJ, Rodger IWB, Thomson NC, eds. *Asthma: basic mechanisms and clinical management*. 3rd ed. San Diego: Academic Press, 1998: 1–33.
- 3 Davies AO, DeLean A, Lefkowitz RJ. Myocardial beta-adrenergic receptors from adrenalectomised rats: impaired formation of high-affinity agonist-receptor complexes. *Endocrinology* 1981;108:720–2.
- 4 Davies AO, Lefkowitz RJ. Regulation of beta-adrenergic receptors by steroid hormones. *Ann Rev Physiol* 1984;46: 119–30.
- 5 Torphy TJ. Beta-receptors, cAMP and airway smooth muscle relaxation: challenges to the dogma. *Trends Pharmacol Sci* 1994;15:370–4.
- 6 Hausdorf WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitisation of beta-adrenergic receptor function. *FASEB J* 1990;4:2881–9.
- 7 McGraw DW, Liggett SB. Heterogeneity of the β -adrenergic receptor kinase expression in the lung accounts for cell-specific desensitisation of the β 2-adrenergic receptor. *J Biol Chem* 1999;272:7338–44.
- 8 Hui KKP, Conolly ME, Tashkin DP. Reversal of human lymphocyte beta-adrenoceptor desensitization by glucocorticoids. *Clin Pharmacol Ther* 1982;32:566–71.
- 9 Barnes PJ. Beta-adrenergic receptors and their regulation. *Am J Respir Crit Care Med* 1995;152:838–60.
- 10 Kobilka BK, Dixon RAF, Frielle T, et al. cDNA for the human beta-adrenergic receptor: a protein with multiple membrane spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet derived growth factor. *Proc Natl Acad Sci USA* 1987;84:46–50.
- 11 Emorine LJ, Marullo S, Delavie-Klutchko C, et al. Structure of the gene for human beta-2 adrenergic receptor: expression and promoter characterisation. *Proc Natl Acad Sci USA* 1987;84:6995–9.
- 12 Hadcock JR, Malbon CC. Regulation of beta-adrenergic receptors by permissive hormones: glucocorticoids increase steady state levels of receptor mRNA. *Proc Natl Acad Sci USA* 1988;85:8415–9.
- 13 Malbon CC, Hadcock JR. Evidence that glucocorticoid response elements in the 5'-non-coding region of the hamster beta-2 adrenergic receptor are obligate for glucocorticoid regulation of receptor mRNA levels. *Biochem Biophys Res Commun* 1988;154:676–81.
- 14 Mak JCW, Nishikawa M, Barnes PJ. Glucocorticoids increase beta-2 adrenergic receptor transcription in human lung. *Am J Physiol* 1995;268:L41–6.
- 15 Mak JCW, Nishikawa M, Shirasaki H, et al. Protective effects of a glucocorticoid on down-regulation of pulmonary beta-2 adrenergic receptors in vivo. *J Clin Invest* 1995; 96:99–106.
- 16 Scarceriaux V, Pelaprat D, Forgez P, et al. Effects of dexamethasone and forskolin on neurotensin production in rat hypothalamic cultures. *Endocrinology* 1995;136:2554–60.
- 17 Dong Y, Aronsson M, Gustafsson JA, et al. The mechanism of cAMP-induced glucocorticoid receptor expression. *J Biol Chem* 1989;264:13679–83.
- 18 Adcock IM, Shirasaki H, Gelder CM, et al. The effects of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung. *Life Sci* 1994;55:1147–53.
- 19 Van der Saag PT, Caldenhoven E, Van der Stolpe A. Molecular mechanisms of steroid action: a novel type of crosstalk between glucocorticoids and NF-kappa B transcription factors. *Eur Respir J* 1996;9(Suppl 22):146–52s.
- 20 Janknecht R, Hunter T. A growing co-activator network. *Nature* 1996;383:22–3.
- 21 Peters MJ, Adcock IM, Brown CR, et al. Beta-adrenoceptor agonists interfere with glucocorticoid receptor DNA binding in rat lung. *Eur J Pharmacol* 1995;289:275–81.
- 22 Peters MJ, Adcock IM, Brown CR, et al. Beta-agonist inhibition of steroid-receptor DNA binding activity in human lung. *Am Rev Respir Dis* 1993;147:A772.

- 23 Stevens DA, Barnes PJ, Adcock IM. Beta-agonists inhibit DNA binding of glucocorticoid responses in human pulmonary and bronchial epithelial cells. *Am J Respir Crit Care Med* 1995;151:A195.
- 24 Hancox RJ, Stevens DA, Adcock IM, *et al.* Effects of inhaled beta-agonist and corticosteroid treatment on nuclear transcription factors in bronchial mucosa in asthma. *Thorax* 1999;54:488–92.
- 25 Korn SH, Wouters EFM, Wesseling G, *et al.* Interaction between glucocorticoids and beta-2-agonists: alpha and beta glucocorticoid-receptor mRNA expression in human bronchial epithelial cells. *Biochem Pharmacol* 1998;56:1561–9.
- 26 Eickelberg O, Roth M, Lox R, *et al.* Ligand-binding activation of the glucocorticoid receptor by beta-2 adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. *J Biol Chem* 1999;274:1005–10.
- 27 Oddera S, Silvestri M, Testi R, *et al.* Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation. *Respiration* 1998;65:199–204.
- 28 Anenden V, Egemba G, Kessel B, *et al.* Salmeterol facilitation of fluticasone-induced apoptosis in eosinophils of asthmatics pre- and post-antigen challenge. *Eur Respir J* 1998;12:157s.
- 29 Pang L, Knox AJ. Synergistic inhibition by β_2 agonists and corticosteroids on TNF α induced IL-8 release from cultured human airway smooth muscle cells. *Am J Respir Cell Mol Biol* 2000 (in press).
- 30 Seldon PM, Stevens, Adcock IM, *et al.* Albuterol does not antagonize the inhibitory effect of dexamethasone on monocyte cytokine release. *Am J Respir Crit Care Med* 1998;157:803–9.
- 31 Nielson CP, Hadjokas NE. Beta-adrenoceptor agonists block corticosteroid inhibition in eosinophils. *Am J Respir Crit Care Med* 1998;157:184–91.
- 32 Geddes BA, Jones TR, Dvorsky RJ, *et al.* Interaction of glucocorticoids and bronchodilators on isolated guinea-pig tracheal and human bronchial smooth muscle. *Am Rev Respir Dis* 1974;110:420–7.
- 33 Stephan WC, Chick TW, Avner BP, *et al.* Tachyphylaxis to inhaled isoproterenol and the effect of methylprednisolone in dogs. *J Allergy Clin Immunol* 1980;65:105–9.
- 34 Ellul-Micallef R, Fenech FF. Effect of intravenous prednisolone in asthmatics with diminished adrenergic responsiveness. *Lancet* 1975;ii:1269–71.
- 35 Pansegrouw DF, Weich DJV, LeRoux FJP. Beta-adrenergic receptor tachyphylaxis in acute severe asthma. *S Afr Med J* 1991;80:229–30.
- 36 Tan KS, Grove A, McLean A, *et al.* Systemic corticosteroid rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. *Am J Respir Crit Care Med* 1997;156:28–35.
- 37 Arnaud A, Charpin J. Interaction between corticosteroids and beta-2 agonists in acute asthma. *Eur J Respir Dis Suppl* 1982;122:126–31.
- 38 Rodrigo G, Rodrigo C. Inhaled fluticasone for acute severe asthma. *Am J Respir Crit Care Med* 1998;157:698–703.
- 39 Pearce N, Crane J, Burgess C, *et al.* Beta-agonists and asthma mortality: déjà vu. *Clin Exp Allergy* 1991;21:401–10.
- 40 McDevitt DG, Shanks RG, Swanton JG. Further observations on the cardiotoxicity of isoprenaline during hypoxia. *Br J Pharmacol* 1974;50:335–44.
- 41 Guideri G, Barletta M, Lehr D. Extraordinary potentiation of isoproterenol cardiotoxicity by corticoid pre-treatment. *Cardiovasc Res* 1974;8:775–86.
- 42 Aziz I, McFarlane LC, Lipworth BJ. Concomitant inhaled corticosteroid resensitises cardiac beta-2 adrenoceptors in the presence of long-acting beta-2 agonist therapy. *Eur J Clin Pharmacol* 1998;54:377–81.
- 43 Lin RY, Newman TG, Sauter D, *et al.* Association between reported use of inhaled triamcinolone and differential short-term responses to aerosolised albuterol in an emergency department setting. *Chest* 1994;106:452–7.
- 44 Taylor DR, Wilkins GT, Herbison GP, *et al.* Interaction between corticosteroid and beta-agonist drugs: biochemical and cardiovascular effects in normal subjects. *Chest* 1995;102:519–24.
- 45 Molino NA, Nannini LJ, Martelli AN, *et al.* Respiratory arrest in near-fatal asthma. *N Engl J Med* 1991;324:285–8.
- 46 Harrison AR, Richards R, Howarth P, *et al.* Interaction of inhaled corticosteroids and beta-2 agonists in asthmatic subjects. *Thorax* 1984;39:710–1.
- 47 Molema J, Lammers J-WJ, Van Herwaarden CLA, *et al.* Effects of inhaled beclomethasone dipropionate on beta-2 receptor function in the airways and adrenal responsiveness in bronchial asthma. *Eur J Clin Pharmacol* 1988;34:577–83.
- 48 Wempe JB, Postma DS, Breederveld N, *et al.* Separate and combined effects of corticosteroids and bronchodilators on airflow obstruction and airway responsiveness in asthma. *J Allergy Clin Immunol* 1992;89:679–87.
- 49 Hjemdahl P, Zetterlund A, Larsson K. Beta-2 agonist treatment reduces beta-2 sensitivity in alveolar macrophages despite corticosteroid treatment. *Am J Respir Crit Care Med* 1996;153:576–81.
- 50 Hancox RJ, Aldridge RE, Cowan JA, *et al.* Tolerance to beta-agonists during acute bronchoconstriction. *Eur Respir J* 1999;14:283–7.
- 51 Newnham DM, Grove A, McDevitt DG, *et al.* Subsensitivity of bronchodilator and systemic beta-2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. *Thorax* 1995;50:497–504.
- 52 Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. *Lancet* 1995;346:201–6.
- 53 Kalra S, Swystun VA, Bhagat R, *et al.* Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. *Chest* 1996;109:953–6.
- 54 Yates DH, Kharitonov SA, Barnes PJ. An inhaled corticosteroid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta-agonist. *Am J Respir Crit Care Med* 1996;154:1603–7.
- 55 Booth H, Bish R, Walters J, *et al.* Salmeterol tachyphylaxis in steroid treated asthmatics. *Thorax* 1996;51:1100–4.
- 56 Simons FER, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. *Pediatrics* 1997;99:655–9.
- 57 Giannini D, Bacci E, Dente FL, *et al.* Inhaled beclomethasone dipropionate reverts tolerance to the protective effects of salmeterol. *Chest* 1999;115:629–34.
- 58 Tan KS, McFarlane LC, Lipworth BJ. Concomitant administration of low dose prednisolone protects against in vivo beta-2 adrenoceptor subsensitivity induced by regular formoterol. *Chest* 1998;113:34–41.
- 59 Crane J, Pearce N, Flatt A, *et al.* Prescribed fenoterol and death from asthma in New Zealand, 1981–83: case control study. *Lancet* 1989;ii:917–22.
- 60 Pearce N, Grainger J, Atkinson M, *et al.* Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977–81. *Thorax* 1990;45:170–5.
- 61 Grainger J, Woodman K, Pearce N, *et al.* Prescribed fenoterol and death from asthma in New Zealand, 1981–87: a further case control study. *Thorax* 1991;46:105–11.
- 62 Gauvreau GM, Jordana M, Watson RM, *et al.* Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. *Am J Respir Crit Care Med* 1997;156:1738–45.
- 63 Aldridge RE, Hancox RJ, Taylor DR, *et al.* Effects of terbutaline and budesonide on sputum inflammatory cells. *Am J Respir Crit Care Med* 2000 (in press).
- 64 Manolitsas ND, Wang J, Devalia JL, *et al.* Regular albuterol, nedocromil sodium and bronchial inflammation in asthma. *Am J Respir Crit Care Med* 1995;151:1925–30.
- 65 Jones SA, Taylor DR. Excessive use of salbutamol: the potential benefits of dose reduction. A case report. *NZ Med J* 1999;112:448–50.
- 66 Van Metre TE. Adverse effects of inhalation of excessive amounts of nebulised isoproterenol in status asthmaticus. *J Allergy* 1969;43:101–13.
- 67 Reisman RE. Asthma induced by adrenergic aerosols. *J Allergy* 1970;46:162–7.
- 68 Wong CS, Wahedna I, Pavord ID, *et al.* Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge. *Am J Respir Crit Care Med* 1994;150:1260–70.
- 69 Cockcroft DW, Swystun VA, Bhagat R. Interaction of inhaled beta-2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. *Am J Respir Crit Care Med* 1995;152:1485–9.
- 70 Haahtela T, Alanko K, Muittari A, *et al.* The superiority of combination beclomethasone and salbutamol over standard dosing of salbutamol in the treatment of chronic asthma. *Ann Allergy* 1989;61:63–6.
- 71 Horn CR, Clark TJH, Cochrane GM. Can the morbidity of asthma be reduced by high dose inhaled therapy? A prospective study. *Respir Med* 1990;84:61–6.
- 72 Waalkens HJ, Gerritsen J, Koeter GH, *et al.* Budesonide and terbutaline or terbutaline alone in children with mild asthma: effects on bronchial hyper-responsiveness and diurnal variation in peak flow. *Thorax* 1991;46:499–503.
- 73 Van Essen Zandvliet EE, Hughes MD, Waalkens HJ, *et al.* Effects of 22 months treatment with inhaled corticosteroid and/or beta-2 agonists on lung function, airway responsiveness and symptoms in children with asthma. *Am Rev Respir Dis* 1992;146:547–54.
- 74 Kerstjens HAM, Brand PLP, Hughes MD, *et al.* A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. *N Engl J Med* 1992;327:1413–9.
- 75 Dompeling E, Van Schayck CP, Van Grunsven PM, *et al.* Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator treatment by adding inhaled corticosteroids. *Ann Intern Med* 1993;118:770–8.
- 76 Dahl R, Pedersen B, Hagglof B. Nocturnal asthma: effect of treatment with oral sustained-release terbutaline, inhaled budesonide, and the two in combination. *J Allergy Clin Immunol* 1989;83:811–5.
- 77 Bennati D, Piacentini GL, Peroni DG, *et al.* Changes in bronchial reactivity in asthmatic children after treatment with beclomethasone alone or in association with salbutamol. *J Asthma* 1989;26:359–64.
- 78 Selroos O, Nyholm J-E. Influence of a budesonide-terbutaline combination on bronchial reactivity. *Clin Exp Allergy* 1990;20:76.
- 79 Wilding PJ, Clark MM, Osborne J, *et al.* Effect of regular terbutaline on the airway response to inhaled budesonide. *Thorax* 1994;51:989–92.

- 80 Barnes PJ, O'Connor BJ. Use of a fixed combination beta-2 agonist and steroid dry powder inhaler in asthma. *Am J Respir Crit Care Med* 1995;151:1053-7.
- 81 Hancox RJ, Cowan JO, Flannery EM, *et al.* Randomised trial of an inhaled beta-agonist, inhaled corticosteroid and their combination in the treatment of asthma. *Thorax* 1999;54:482-7.
- 82 Verberne AAPH, Frost C, Roorda RJ, *et al.* One year treatment with salmeterol compared with beclomethasone in children with asthma. *Am J Respir Crit Care Med* 1996;156:688-95.
- 83 Simons FE. A comparison of beclomethasone, salmeterol and placebo in children with asthma. *N Engl J Med* 1997;337:1659-65.
- 84 Greening AP, Ind PW, Northfield M, *et al.* Added salmeterol versus higher dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. *Lancet* 1995;344:219-24.
- 85 Woolcock A, Lundback B, Ringdal N, *et al.* Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. *Am J Respir Crit Care Med* 1996;153:1481-8.
- 86 Pearlman DS, Stricker W, Weinstein W, *et al.* Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. *Ann Allergy Asthma Immunol* 1999;82:257-65.
- 87 Van Noord JA, Schreurs AJM, Mol SJM, *et al.* Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. *Thorax* 1999;54:207-12.
- 88 Weersink EJ, Douma RR, Postma DS, *et al.* Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. *Am J Respir Crit Care Med* 1997;155:1241-6.
- 89 Murray JJ, Church JL, Anderson WH, *et al.* Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. *Allergy Asthma Proc* 1999;20:173-80.
- 90 Baraniuk J, Murray JJ, Nathan RA, *et al.* Fluticasone alone or in combination with salmeterol vs. triamcinolone in asthma. *Chest* 1999;116:625-32.
- 91 Russell G, Williams DAJ, Weller P, *et al.* Salmeterol xinafoate in children on high dose inhaled steroids. *Ann Allergy Asthma Immunol* 1995;75:423-8.
- 92 Van der Molen T, Postma DS, Turner MO, *et al.* Effects of the long-acting beta-agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. *Thorax* 1996;52:535-9.
- 93 Pauwels RA, Lofdahl C-G, Postma DS, *et al.* Effect of inhaled formoterol and budesonide on exacerbations of asthma. *N Engl J Med* 1997;337:1405-11.
- 94 Taylor DR, Town GI, Herbison GP, *et al.* Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. *Thorax* 1998;53:744-52.
- 95 Leblanc P, Knight A, Kreisman H, *et al.* A placebo-controlled, cross-over comparison of salmeterol and salbutamol in patients with asthma. *Am J Respir Crit Care Med* 1996;154:324-8.
- 96 Pedersen B, Faurschou P, Madsen F, *et al.* Salmeterol treatment reduces the need for inhaled steroid in steroid-dependent asthmatics: a randomised, double-blind placebo-controlled parallel-group study. *Eur Respir J* 1996;9:50s.
- 97 Sears MR, Taylor DR, Print CG, *et al.* Regular inhaled beta-agonist treatment in bronchial asthma. *Lancet* 1990;336:1391-6.
- 98 Taylor DR, Sears MR, Herbison GP, *et al.* Regular inhaled beta-agonist: effects on exacerbations and lung function. *Thorax* 1993;48:134-8.